MAPK8 and non-small cell lung carcinoma: Notably, JNK-IN-8 treatment did not affect the MSLN expression but did efficiently attenuate MET activation in NSCLC cells overexpressing MSLN, whereas crizotinib had no effect on MSLN expression and JNK signaling (Fig. 5C-D, E-G).